Observational Study
Copyright ©The Author(s) 2023.
World J Hepatol. Aug 27, 2023; 15(8): 985-1000
Published online Aug 27, 2023. doi: 10.4254/wjh.v15.i8.985
Figure 1
Figure 1 Flow chart of the study population inclusion process. MAFLD: Metabolic associated fatty liver disease; NAFLD: Non-alcoholic fatty liver disease.
Figure 2
Figure 2 Prevalence of metabolic associated fatty liver disease and non-alcoholic fatty liver disease. MAFLD: Metabolic associated fatty liver disease; NAFLD: Non-alcoholic fatty liver disease.
Figure 3
Figure 3 Participants with metabolic associated fatty liver disease, non-alcoholic fatty liver disease, and those excluded by the two definitions. MAFLD: Metabolic associated fatty liver disease; NAFLD: Non-alcoholic fatty liver disease.
Figure 4
Figure 4 Prevalence of metabolic associated fatty liver disease by gender and age group. MAFLD: Metabolic associated fatty liver disease.
Figure 5
Figure 5 Prevalence of non-alcoholic fatty liver disease by gender and age group. NAFLD: Non-alcoholic fatty liver disease.
Figure 6
Figure 6 Non-alcoholic fatty liver disease and metabolic associated fatty liver disease prevalence by body mass index zone. MAFLD: Metabolic associated fatty liver disease; NAFLD: Non-alcoholic fatty liver disease; BMI: Body mass index.